Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Shanghai Jiao Tong University School of Medicine
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
70High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03258320CT.gov A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients | — | Recruiting | — | — | — |
NCT01522443CT.gov Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer | — | Terminated | — | — | — |
NCT01204710CT.gov A Study of Olaratumab (IMC-3G3) in Prostate Cancer | — | Completed | — | — | — |
NCT00770848CT.gov AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer | — | Completed | — | — | — |
NCT00683475CT.gov A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer | — | Completed | — | — | — |
NCT00385827CT.gov A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC) | — | Terminated | — | — | — |
NCT00627354CT.gov Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | — | Completed | — | — | — |
NCT00327340CT.gov Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC | — | Completed | — | — | — |
NCT00331344CT.gov Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy | — | Completed | — | — | — |
NCT00182741CT.gov Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer | — | Completed | — | — | — |
Show 14 more trialsShow fewer
NCT00124566CT.gov Study of Irofulven in Patients With Hormone-refractory Prostate Cancer | — | Completed | — | — | — |
NCT00059631CT.gov Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone | — | Completed | — | — | — |
NCT00058084CT.gov Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00005847CT.gov Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | — | Completed | — | — | — |
NCT00017563CT.gov Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer | — | Completed | — | — | — |
NCT00004124CT.gov S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer | — | Completed | — | — | — |
NCT00004001CT.gov S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy | — | Completed | — | — | — |
NCT00004071CT.gov Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer | — | Completed | — | — | — |
NCT00006114CT.gov Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | — | Unknown | — | — | — |
NCT00003633CT.gov Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer | — | Unknown | — | — | — |
NCT00003343CT.gov Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00003232CT.gov Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00003183CT.gov Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer | — | Unknown | — | — | — |
NCT00003858CT.gov Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for Recurrence | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Mitoxantrone (this asset) | Shanghai Jiao Tong University School of Medicine | P3 | BB · 67 |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BBB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BBB |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BB |
| Goserelin | Bayer | P4 | BB |
| Prednisone | Mayo Clinic | P4 | BB |
| Flutamide | VA Office of Research and Development | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Mitoxantrone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Promyelocytic Leukemia | — | P4 | BBB · 72 |
| Acute Monocytic Leukemia | — | P2/3 | BBB · 72 |
| Myeloid Neoplasm | — | P3 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Mitoxantrone in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/mitoxantrone-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →